Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actonel and Whole Body Vibration in Children with Osteogenesis Imperfecta
NCT03208582Phase 2Completed
- Sponsor
- Sheffield Children's Hospital
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of risedronate in osteogenesis imperfecta (OI), sponsored by Sheffield Children's Hospital. Primary endpoint: Procollagen Type 1 N-Terminal Propeptide response at 99 days. Started Apr 2017; status: completed.
02
Drugs
risedronate
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03208582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208582.